VERISILICON
9.4.2024 09:01:28 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced its demonstration at Embedded World 2024 in Nuremberg, Germany, booth numbered Hall 4A-518, where it is showcasing customers’ various leading products leveraging the company’s latest technologies and advanced solutions.
VeriSilicon’s one-stop custom silicon services and semiconductor IP licensing services provide customers with intelligent, secure, and highly adaptable solutions, addressing a wide range of key areas such as Artificial Intelligence (AI) and Machine Learning, Internet of Things (IoT), Consumer Electronics and Smart Devices, Data Center and High-Performance Computing, Smart Healthcare, and Automotive Electronics. Highlighted demonstrations include:
- AI and Machine Learning: A high-performance AI-PC with Blue Ocean’s chiplet acceleration card using GPGPU and NPU IPs powered by VeriSilicon, Google Open Se Cura powered by VeriSilicon, Inuitive vision AI processor featuring VeriSilicon’s dual-channel Image Signal Processor (ISP) IP.
- IoT: VeriSilicon’s LE Audio compliant complete Bluetooth Low Energy IP solution, LE Mesh system solution based on VeriSilicon’s BLE technology.
- Consumer Electronics and Smart Devices: A next-generation 8K TV and a leading Smart Camera integrated with VeriSilicon’s Neural Network Processor (NPU) IP, a next-generation Drone featuring VeriSilicon’s Video Processor Unit (VPU) IP, Smart Watches and Smart AR Glasses based on VeriSilicon’s Graphics Processor Unit (GPU) IP and Display Processor IP, Smart Home devices embedded with VeriSilicon’s IPs.
- Data Center and High-Performance Computing: VeriSilicon’s second-generation data center video transcoding platform solution.
- Smart Healthcare: VeriHealthi health monitoring platform based on VeriSilicon’s ZSP Digital Signal Processor (DSP) and BLE IPs.
- Automotive Electronics: Automotive SoC enabled by VeriSilicon’s ISO 26262 compliant IPs and subsystems.
VeriSilicon’s semiconductor IP licensing business holds the largest market share in China and ranks seventh worldwide1. Among the top ten IP companies globally, VeriSilicon’s number of IP categories ranks top two2. With over two decades of expertise in the GPU sector, VeriSilicon’s GPU IP has been shipped in nearly two billion chips. Additionally, VeriSilicon’s self-developed NPU IP has been integrated into 128 AI SoCs supplied by 72 licensees in more than 10 market segments, and has been shipped in over 100 million AI-enabled chips worldwide. In terms of video processing, VeriSilicon’s first-generation video transcoding acceleration solution, which is integrated with the company’s VPU IP, provides 6 times the transcoding capability of traditional high-end CPUs while consuming only 1/13 of the power. This innovative technology has been successfully applied to media accelerator chips custom-made for leading global chip companies based on the 5nm process and has entered the mass production stage.
As part of the Embedded World conference program, VeriSilicon’s Vice President of Vision Image Product Shang-Hung Lin will deliver a keynote speech themed Implementing Transformer Neural Networks for Visual Perception on Embedded Devices during Session 7.8 on Embedded Vision & Edge AI, scheduled for April 10 at 1:45pm.
“We are thrilled to present our latest and innovative IP solutions at Embedded World 2024. Our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio is silicon-proven, production-proven, and application-proven, which is configurable for a wide range of applications, ranging from low-power-focused to high-performance data center uses,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “In addition to our own IP offerings, we have also collaborated with third-party partners such as RISC-V IP providers and GUI software providers to deliver competitive solutions to our customers. Our commitment to IP innovations is aimed at empowering our customers’ success, enabling them to introduce innovative products to the market more quickly.”
To experience live demos and engage with VeriSilicon’s experts, please visit our booth at Messezentrum Nürnberg (Booth No.: Hall 4A-518) or schedule a meeting with us via email at eu-sales@verisilicon.com.
1 According to IPnest, April 2023
2 According to IPnest’s IP categorization and companies’ disclosure information
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409713011/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom